Claritas Acquires Global Rights to R-107 for PAH, Other Lung Diseases

Claritas Acquires Global Rights to R-107 for PAH, Other Lung Diseases

314991

Claritas Acquires Global Rights to R-107 for PAH, Other Lung Diseases

Claritas Pharmaceuticals now has exclusive worldwide rights to develop and market R-107 — a liquid form of nitric oxide — for the treatment of pulmonary diseases such as pulmonary arterial hypertension (PAH), acute respiratory distress syndrome (ARDS), and persistent pulmonary hypertension of the newborn (PPHN). In its announcement of the deal, Claritas said R-107 has issued and pending patents in some 40 countries, including the U.S., Australia, Brazil, China, India, Japan, Russia, and South Korea. Patents also…

You must be logged in to read/download the full post.